CDMO News
ABVC BioPharma Sustains Profitable Global Licensing Deals and a Promising CDMO Acquisition, Enhancing Growth Prospects
ABVC BioPharma, a clinical-stage biopharmaceutical company, has provided an update on its expected cash milestone payments and CDMO investment. The company forecasts $19 million in licensing revenue in 2025, driven by three global licensing agreements. Additionally, ABVC’s $60 million CDMO
24 March 2025
Stay ahead of trends and best practices
